Search - tctmd.com

Displaying 381 - 400 of 423

Sort: Relevancy | Date

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

October 11, 2013

News Daily News

La Aspirina a Largo Plazo es tan Eficaz como la Terapia Doble en Pacientes SLF Sin Complicaciones

October 11, 2013

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Presentation

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Presenter: C.W. Lee

October 10, 2013

HOST-ASSURE: Adjunctive Cilostazol vs. Double-Dose Clopidogrel After DES Implantation

Presentation

HOST-ASSURE: Adjunctive Cilostazol vs. Double-Dose Clopidogrel After DES Implantation

Presenter: K. W. Park

September 17, 2013

Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of DES

Presentation

Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of DES

Presenter: Gregg W. Stone

July 30, 2013

News Daily News

HORIZONS-AMI: La Bivalirudina y Taxus Mejoran los Resultados en Pacientes sometidos a una PCI en la Arteria Descendente Anterior Izda

July 11, 2013

News Daily News

HORIZONS-AMI: Bivalirudin, Taxus Improve Outcomes in LAD PCI Patients

July 11, 2013

Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary PCI of the LAD

Presentation

Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary PCI of the LAD

Presenter: Jochen W?hrle

July 09, 2013

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presentation

ADAPT-DES One-Year Results: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel and Aspirin Hyporesponsiveness on Patient Outcomes

Presenter: Gregg W. Stone

March 26, 2013

News Daily News

La Duración Ideal de la Terapia Antiplaquetaria Doble podría Depender del Tipo de Stent

January 22, 2013

News Daily News

Ideal Duration of Dual Antiplatelet Therapy May Depend on Stent Type

January 22, 2013

News Daily News

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

December 05, 2012

News Daily News

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

November 20, 2012

News Daily News

Estudio muestra el impacto de la comunicación de salud pública en el uso de clopidogrel después de la colocación de un SLF

November 20, 2012

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Presentation

RESET Trial: A New Strategy for Discontinuation of Dual Antiplatelet Therapy

Presenter: B-K Kim

September 19, 2012

Double Antiplatelet Therapy After DES Implantation

Presentation

Double Antiplatelet Therapy After DES Implantation

Presenter: I. Ferreira-Gonz?lez

September 19, 2012

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Presentation

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Presenter: Ryota Sakurai

July 12, 2012

Prolonged Clopidogrel Use After BMS and DES Placement: The VA Drug-Eluting Stent Study

Presentation

Prolonged Clopidogrel Use After BMS and DES Placement: The VA Drug-Eluting Stent Study

Presenter: David P. Faxon

June 08, 2012

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Presentation

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Presenter: T. Tada

June 01, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.